Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients

被引：0
|
作者：
Rendo, Pablo [1 ]
Berntorp, Erik [2 ]
Keeling, David M. [3 ]
Makris, Michael [4 ]
Hermans, Cedric R. [5 ]
Mauser-Bunschosten, Ereline Pauline [6 ]
Musso, Roberto [7 ]
Tagliaferri, Annarita [8 ]
Kollmer, Carl
Baumann, James
Charnigo, Robert
机构：
[1] Pfizer, Clin Affairs, Collegeville, PA USA
[2] Malmo Univ Hosp, Dept Clin Sci, Malmo, Sweden
[3] Oxford Haemophilia & Thrombosis Ctr, Oxford, England
[4] Sheffield Teaching Hosp Trust, Dept Haematol, Sheffield, S Yorkshire, England
[5] Clin Univ St Luc, B-1200 Brussels, Belgium
[6] Univ Medich Ctr Utrecht, Utrecht, Netherlands
[7] Azienda Osped Ferrarotto, Catania, Italy
[8] Osped Maggiorore, Ctr Emostasi & Curaemofilia, Parma, Italy
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1504 / 1504
页数：1
相关论文
共 50 条
  • [31] The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B
    Shapiro, AD
    Di Paola, J
    Cohen, A
    Pasi, KJ
    Heisel, MA
    Blanchette, VS
    Abshire, TC
    Hoots, WK
    Lusher, JM
    Negrier, C
    Rothschild, C
    Roth, DA
    [J]. BLOOD, 2005, 105 (02) : 518 - 525
  • [32] Recombinant factor IX in the treatment of previously-treated patients with hemophilia B
    White, G
    Shapiro, A
    Lusher, J
    Roth, D
    Pasi, J
    Keutzer, T
    Courter, S
    Tubridy, K
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 609 - 609
  • [33] Recombinant factor IX in the treatment of previously-treated patients with hemophilia B
    White, G
    Pasi, KJ
    Lusher, J
    Brackmann, HH
    Magill, M
    Courter, S
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : PS211 - PS211
  • [34] Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients
    Collins, P. W.
    Quon, D. V. K.
    Makris, M.
    Chowdary, P.
    Kempton, C. L.
    Apte, S. J.
    Ramanan, M. V.
    Hay, C. R. M.
    Drobic, B.
    Hua, Y.
    Babinchak, T. J.
    Gomperts, E. D.
    [J]. HAEMOPHILIA, 2018, 24 (01) : 104 - 112
  • [35] Recombinant factor IX (BAX326) in pediatric PTPs with hemophilia B: a prospective clinical trial
    Urasinski, Tomasz
    Stasyshyn, Oleksandra
    Andreeva, Tatiana
    Rusen, Luminita
    Perina, Farida G.
    Oh, Myungshin
    Chapman, Miranda
    Pavlova, Borislava G.
    Wong, Wing-Yen
    Abbuehl, Brigitt E.
    [J]. HAEMOPHILIA, 2014, 20 : 27 - 27
  • [36] A PHARMACOKINETIC EVALUATION OF RECOMBINANT HUMAN FACTOR-IX (RHFIX) IN PATIENTS WITH SEVERE HEMOPHILIA-B
    WHITE, GC
    SHAPIRO, AD
    RAGNI, MV
    COURTER, SG
    TUBRIDY, KL
    KAYE, JA
    KESSLER, CM
    [J]. THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1015 - 1015
  • [37] A prospective post-authorization safety surveillance study in Japanese hemophilia B patients with recombinant factor IX Fc fusion protein (rFIXFc)
    Hanabusa, Hideji
    Higasa, Satoshi
    Taki, Masashi
    Kobayashi, Masao
    Hashizume, Akio
    Makioka, Haruki
    Shiraishi, Mutsumi
    Hirakata, Toshiyuki
    [J]. HAEMOPHILIA, 2016, 22 : 52 - 52
  • [38] Use of recombinant activated factor vii in pediatric patients without hemophilia
    Muwakkit, S. A.
    Majdalani, M. M.
    Musallem, K. M.
    Saab, R.
    Abboud, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 858 - 858
  • [39] HUMAN FACTOR-IX IN PATIENTS WITH HEMOPHILIA B AND ON WARFARIN THERAPY
    THOMPSON, AR
    [J]. CIRCULATION, 1976, 54 (04) : 118 - 118
  • [40] Phase I/II pharmacokinetics, safety, and efficacy data of recombinant human factor IX in previously treated patients with hemophilia B.
    White, G
    Shapiro, A
    Ragni, M
    Kaye, J
    Tubridy, K
    McCarthy, K
    Courter, S
    [J]. BLOOD, 1995, 86 (10) : 761 - 761
12345